Facial skin infection with Ochroconis mirabilis

J Mycol Med. 2021 Jun;31(2):101126. doi: 10.1016/j.mycmed.2021.101126. Epub 2021 Mar 14.

Authors

Raphaël André¹, Béatrice Ninet-Bescher², Lionel Fontao³

Affiliations

¹ Division of dermatology, Geneva University Hospitals, Geneva, Switzerland. Electronic address: Raphael.andre@hcuge.ch.
² Division of laboratory medicine, Geneva University Hospitals, Geneva, Switzerland.
³ Division of dermatology, Geneva University Hospitals, Geneva, Switzerland; Division of laboratory medicine, Geneva University Hospitals, Geneva, Switzerland.

PMID: 33774387
DOI: 10.1016/j.mycmed.2021.101126

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Administration, Topical
Adult
Antifungal Agents / pharmacology
Antifungal Agents / therapeutic use
Ascomycota / drug effects
Ascomycota / isolation & purification
Ascomycota / pathogenicity*
Face / microbiology*
Humans
Male
Microbial Sensitivity Tests
Mycoses / microbiology*
Skin / drug effects
Skin / microbiology*
Skin / pathology
Switzerland
Treatment Outcome

Substances

Antifungal Agents

Supplementary concepts

Ochroconis mirabilis